Trial site
ALERGO-MED OŚRODEK BADAŃ KLINICZNYCH Sp. z o.o.
Tarnów, Lesser Poland Voivodeship 33-100, PolandEU-13 widening countryNot linked to an institution yet
- 14running trials
- 12closed trials
The trials here
What the 26 trials at this site are about, from their registry records.
- Phase
- Phase 317 trials
- Phase 29 trials
- Status
- Completed11 trials
- Active, not recruiting6 trials
- Recruiting5 trials
- Not yet recruiting2 trials
- Enrolling by invitation1 trial
- Withdrawn1 trial
- Lead sponsor
- Sanofi3 trials
- Amgen Inc.2 trials
- AstraZeneca2 trials
- Celldex Therapeutics2 trials
- Chiesi Farmaceutici S.p.A.2 trials
- and 12 more
Running trials
Recruiting
A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluate the efficacy and safety of QVM149 (indacaterol acetate / glycopyrronium bromide / mometasone furoate) compared to salmeterol xinafoate/fluticasone propionate in children from 12 years to less than 18 years of age with asthma.
2022-502365-26-00· Phase 3· Novartis Pharma AG· Source
Recruiting
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis
NCT07660835· Phase 2· Galderma R&D· Source
Recruiting
A Phase 2 Study of Lesigercept (YH35324) in Adult Patients with Chronic Spontaneous Urticaria (CLEAR)
2025-524006-14-00· Phase 2· Yuhan Corp.· Source
Recruiting
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria
2025-522878-36-00· Phase 3· Celldex Therapeutics Inc.· Source
Recruiting
A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma
NCT07525375· Phase 2· AstraZeneca· Source
Recruiting
Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines
NCT07415551· Phase 2· Yuhan Corporation· Source
Contact: JinHyun Choi
Recruiting
Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma
NCT07301736· Phase 2· Chiesi Farmaceutici S.p.A.· Source
Enrolling by invitation
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT07256392· Phase 3· Celldex Therapeutics· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
NCT07037901· Phase 2· Inmagene LLC· Source
Active, not recruiting
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
NCT06966479· Phase 2· Upstream Bio Inc.· Source
Active, not recruiting
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT06455202· Phase 3· Celldex Therapeutics· Source
Active, not recruiting
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06407934· Phase 3· Sanofi· Source
Enrolling by invitation
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
NCT06191315· Phase 3· Sanofi· Source
Active, not recruiting
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT06136741· Phase 2· Nektar Therapeutics· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error